Breath Test for Chemicals (Volatile Organic Compounds)

This study has been completed.
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT01437033
First received: September 16, 2011
Last updated: August 23, 2014
Last verified: July 2014
  Purpose

Background:

- Some types of cancer, like cancer of the esophagus, are difficult to detect at an early stage. A possible detection method involves collecting breath samples to look for chemicals that may be signs of cancer. However, more research is needed to determine how different chemicals appear in different breath samples. This study will involve healthy volunteers.

Objectives:

- To study chemicals appearing in breath samples of healthy volunteers.

Eligibility:

- Healthy volunteers between 30 and 60 years of age.

Design:

  • Participants will fast overnight (midnight to morning) and then provide two breath samples taken 5 minutes apart.
  • Breath samples will be collected on days 1, 49, and 98 of the study

Condition
Breath Tests
Human Volunteers
Pilot Study

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: A Pilot Study of a Breath Test for Assessment of Volatile Organic Compounds

Resource links provided by NLM:


Further study details as provided by National Institutes of Health Clinical Center (CC):

Primary Outcome Measures:
  • Statistics of robustness (CV, ICCs) [ Time Frame: 98 days ] [ Designated as safety issue: No ]

Estimated Enrollment: 5
Study Start Date: August 2011
Detailed Description:

Background:

Although breath tests are common for specific uses where the biomarker is highly concentrated (e .g. alcohol, urea for Helicobacter prylori infection), lower concentration compounds in the breath can also provide information on exogenous exposures and endogenous metabolic processes.

Employing standardized collection techniques and high sensitivity measurement technologies have shown that breath profiles can accurately identify people with diseases such as breast cancer and lung cancer.

Breath profiling technologies have great potential as non-invasive tools for diagnosis and risk stratification of precancerous disease as well as elucidation of the causes of cancer.

Prior to using breath profiles for these purposes it is essential to assess how much of the breath profile and which parts of the breath profile are relatively stable over a period of time.

Objectives:

The primary objective of this pilot study is to assess the intra-individual variability of breath profiles sampled over a period of 98 days.

Eligibility:

DCEG volunteers aged 30-60 years, inclusive.

Design:

Pilot study.

Five DCEG volunteers will be enrolled for this study.

We will assess breath profiles sampled in duplicate at three time periods (days 1, 49 and 98).

We will calculate a coefficients of variation (CV) to determine the proportion and parts of the breath profile which have values less than 10% when collected on the same day,49 days apart, and 98 days apart.

  Eligibility

Ages Eligible for Study:   30 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria
  • INCLUSION CRITERIA:

DCEG volunteers aged 30-60 years, inclusive.

EXCLUSION CRITERIA:

Aged less than 30 years. Aged 61 years or older. Individuals who identify themselves to be in any one of the following categories over the next 4 month period:

  • Plan to initial a large change in their daily amount of physical activity
  • Plan to make large changes to their diet (reduce caloric intake, become a vegetarian etc)
  • May possibly move away from the area for a new job, sabbatical, retirement etc
  • Plan to attempt to become pregnant
  • Have limited availability for any reason including prolonged vacation or business travel
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01437033

Locations
United States, Maryland
National Cancer Institute (NCI), 9000 Rockville Pike
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
Investigators
Principal Investigator: Michael B Cook, M.D. National Cancer Institute (NCI)